CTMX — CytomX Therapeutics, Inc. stock price, charts and financials

QT43CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
3.44
-0.02-0.58%
OverviewShort InterestFilings
CTMXQT43CytomX Therapeutics, Inc.·NASDAQ
3.44-0.58%
TA
Loading chart...
Signal & projected range
Earnings big miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.52%$15.45MESO+4.64%$16.68ZBIO-1.48%$31.95GHRS-2.44%$29.53TSHA-2.90%$6.37STOK-1.47%$32.23ABCL+34.78%$9.34VRDN-2.25%$23.06
Snapshot
Index-P/E-EPS (ttm)0.50Insider Own5.73%Shs Outstand217.70MPerf Week11.61%
Market Cap753.25MForward P/E-EPS next Y-0.50Insider Trans-2.09%Shs Float173.12MPerf Month-12.63%
Enterprise Value741.73MPEG0.05EPS next Q-Inst Own-Short Float23.29%Perf Quarter-13.50%
Income-79.17MP/S41.16EPS this Y-183.13%Inst Trans-Short Ratio9.51Perf Half Y-33.97%
Sales18.30MP/B2.51EPS next Y-19.39%ROA-20.89%Short Interest40.32MPerf YTD-18.78%
Book/sh-P/C-EPS next 5Y-ROE-38.46%52W High8.16 -57.86%Perf Year59.45%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-25.42%52W Low1.71 101.16%Perf 3Y102.34%
Dividend Est.-EV/EBITDA-Sales past 3/5Y12.77% 2.25%Gross Margin98.63%Volatility4.59% 5.05%Perf 5Y-36.04%
Dividend TTM-EV/Sales40.53EPS Y/Y TTM31.58%Oper. Margin-476.19%ATR (14)0.18Perf 10Y-65.47%
Dividend Ex-Date-Quick Ratio9.36Sales Y/Y TTM6.52%Profit Margin-435.21%RSI (14)53.22Recom2.19
Dividend Gr. 3/5Y-Current Ratio9.36EPS Q/Q-137.04%SMA201.97%Beta2.14Target Price11.25
Payout0.00%Debt/Eq0.02Sales Q/Q-80.39%SMA502.87%Rel Volume0.60Prev Close3.46
Employees69LT Debt/Eq-0.19EarningsNov 10SMA200-17.30%Avg Volume4.11MPrice3.44
IPO DateOct 08, 2015Option/ShortYes / YesEPS/Sales Surpr.17.42% 119.08%Net Debt/EBITDA0.15Volume2,461,313Change-0.58%
Analyst Ratings
DateActionAnalystRatingTarget
May-19-26InitiatedWolfe ResearchOutperform$6.00
May-11-26ReiteratedHC Wainwright & Co.Buy$11
Mar-18-26ReiteratedJefferiesBuy$8.00
Mar-16-26ReiteratedOppenheimerPerform$7.00 → $12
Mar-16-26UpgradeJP MorganNeutral → Overweight
Feb-04-26ReiteratedBarclaysOverweight$8.00 → $10
Jan-20-26InitiatedGuggenheimBuy$10
Jan-20-26ReiteratedBarclaysOverweight$6.00 → $8.00
Jan-20-26ReiteratedPiper SandlerOverweight$3.25 → $10
Oct-21-25ReiteratedBarclaysOverweight$3.50 → $6.00
Latest News
Aug-07-26
Aug-07-2612:02AM
CytomX Therapeutics (NASDAQ:CTMX) Shares Plunge After Q2 Revenue and EPS Miss EstimatesChartMill
Aug-06-26
Aug-06-2610:44PM
CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcriptseekingalpha.com
09:05PM
CytomX Therapeutics Q2 Earnings Call Highlightsmarketbeat.com
08:12PM
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimateszacks.com
04:15PM
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Updateglobenewswire.com
Aug-03-26
Aug-03-2608:00AM
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officerglobenewswire.com
Jul-30-26
Jul-30-2608:00AM
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026globenewswire.com
Jul-29-26
Jul-29-2603:45AM
ADAR1 Capital Management LLC Sells 872,579 Shares of CytomX Therapeutics, Inc. $CTMXdefenseworld.net
Jul-27-26
Jul-27-2608:00AM
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directorsglobenewswire.com
Jul-08-26
Jul-08-2601:01PM
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Whyzacks.com
Company

CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue76138101——————
Cost of Goods Sold Incl. D&A
000——————
Gross Profit76138101——————
Selling, General and Administrative Excl. Other303030——————
Research and Development698378——————
Other Operating Expense
000——————
Operating Income-2225-6——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)5710——————
Net Income Before Taxes-17323——————
Income Taxes004——————
Consolidated Net Income-1732-1——————
Net Income From Continuing Operations-1732-1——————
Net Income-1732-1——————
EPS (Recurring)-0.150.38-0.01——————
EPS (Basic, Before Extraordinaries)-0.150.38-0.01——————
EPS (Diluted)-0.150.38-0.01——————
EBITDA-16345——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio—2.71———————
Price To Sales Ratio7.740.631.14——————
Gross Margin100.00100.00100.00——————
Operating Margin-28.9518.12-5.94——————
Net Margin-22.3723.19-0.99——————
Shares Outstanding1388474——————
Market Capitalization58887115——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$7.50$5.88$4.25$2.63$1.01● Close Price0.00M0.31M0.61M0.92M1.23MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Ogden ChristopherChief Financial OfficerJun 15 '26Sale3.051,6244,953295,324Jun 17
Chu Yu-WayeChief Medical OfficerMar 17 '26Sale6.4221,279136,675189,446Mar 19
McCarthy Sean A.CEOMar 17 '26Sale6.42118,969764,1381,078,922Mar 19
BELVIN MARCIASVP, Chief Scientific OfficerMar 17 '26Sale6.4231,492202,273300,760Mar 19
Ogden ChristopherChief Financial OfficerMar 17 '26Sale6.4219,323124,112296,948Mar 19
McCarthy Sean A.CEONov 06 '25Sale4.54101,793461,906987,891Nov 10
BELVIN MARCIASVP, Chief Scientific OfficerJun 16 '25Sale2.6913,88437,334272,252Jun 17
Ogden ChristopherChief Financial OfficerJun 16 '25Sale2.6910,61428,540226,271Jun 17
McCarthy Sean A.CEOJun 16 '25Sale2.6955,511149,2641,089,684Jun 17
McCarthy Sean A.CEOJun 13 '25Option Exercise0.00150,00001,145,195Jun 17
BELVIN MARCIASVP, Chief Scientific OfficerJun 13 '25Option Exercise0.0037,5000286,136Jun 17
Ogden ChristopherChief Financial OfficerJun 13 '25Sale2.951,6414,841199,385Jun 17
Ogden ChristopherChief Financial OfficerJun 13 '25Option Exercise0.0037,5000236,885Jun 17
McCarthy Sean A.CEOMar 18 '25Sale0.6037,65622,556995,195Mar 20
Ogden ChristopherChief Financial OfficerMar 18 '25Sale0.608,5515,122201,026Mar 20
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.